|
2024
|
Invention
|
Fluorinated empathogens.
Provided are fluorinated analogs of MDMA, including fluorinated empatho... |
|
|
Invention
|
Use of deuterated empathogens as therapeutic agents. Provided are deuterated analogs of MDMA, inc... |
|
|
Invention
|
Asymmetric phenylalkylamines. Provided herein are substituted phenylalkylamine analogs, such as 2... |
|
|
Invention
|
Phenylalkylamine prodrugs. Provided herein are prodrugs of phenylalkylamines (e.g., psychedelic p... |
|
|
Invention
|
Asymmetric allyl tryptamines. Provided are allyl tryptamines, such as asymmetric allyl tryptamine... |
|
|
Invention
|
Deuterated and fluorinated empathogens. Provided are deuterated and/or fluorinated empathogen com... |
|
2023
|
Invention
|
N-substituted phenylalkylamines and their use as therapeutic agents |
|
|
Invention
|
N-substituted phenylalkylamines and their use as therapeutic agents. Provided are N-substituted p... |
|
2022
|
Invention
|
Substituted phenylalkylamines.
Provided are phenylalkylamines, such as 2,5-disubstituted and 2,4... |
|
|
Invention
|
Substituted phenylalkylamines. Provided are phenylalkylamines, such as 2, 5 -disubstituted and 2,... |
|
|
Invention
|
Fluorinated empathogens. Provided are fluorinated analogs of MDMA, including fluorinated empathog... |
|
|
Invention
|
Deuterated empathogens. Provided are deuterated analogs of MDMA, including deuterated empathogens... |
